Sponsors (4)
The bill tightens export controls on synthetic DNA/RNA to strengthen national biodefense and protect biotech IP, but does so at the cost of new licensing/compliance burdens that could slow research, hinder international collaboration, and raise costs for institutions and consumers.
Taxpayers and the general public: restricts transfers of novel synthetic DNA/RNA sequences to foreign entities of concern, reducing the risk that adversaries can accelerate biological threats and strengthening U.S. biodefense.
Researchers, tech workers, and regulators: defines key terms (digital sequence, synthetic DNA/RNA, foreign entity of concern) and aligns export controls with broader U.S. efforts to limit sensitive-tech access, creating clearer regulatory expectations and strategic coherence.
Scientists and small biotech companies: reduces risk of intellectual-property theft by limiting exports of sensitive sequence data, helping protect commercial research outputs.
Scientists, biotech firms, and tech workers: new licensing requirements and expanded export controls will impose administrative burdens, fees, and delays on exporting digital DNA/RNA sequences, increasing research and development costs and slowing projects.
Researchers, students, and international collaborators: export restrictions may hinder legitimate cross-border scientific collaboration and data-sharing, slowing innovation and public-health research (including pandemic response and shared studies).
Universities, financial institutions, and small businesses: expanding controls and some definitional ambiguities increase compliance costs and risk uneven enforcement or uncertainty about what needs licensing.
Based on analysis of 3 sections of legislative text.
Requires a license within one year to export, reexport, or transfer in‑country any digital sequence of synthetic DNA or RNA to specified foreign entities of concern, with limited regulatory exceptions.
Introduced December 11, 2025 by Thomas Bryant Cotton · Last progress December 11, 2025
Requires a federal export license, within one year after the law is enacted, for sending any digital sequence of synthetic DNA or RNA (whether designed by humans or AI) to certain foreign entities tied to countries of concern. It adds this licensing rule into existing U.S. export control law, defines key terms (like “digital sequence,” “synthetic DNA/RNA,” and “foreign entity of concern”), and notes concerns about foreign exploitation of U.S. biotech intellectual property, especially by the People’s Republic of China. The rule uses established export control exceptions (including those in 15 C.F.R. § 734.3(b) ) to narrow coverage, and it creates new compliance obligations for companies, researchers, and others who export or transfer digital genetic sequence data to listed foreign entities or jurisdictions.